REFERENCES
- Dare A J, Veinot J P, Edwards W D, et al. New observations on the etiology of aortic valve disease: a surgical pathological study of 236 cases from 1990. Hum Pathol 1993; 24: 1330–1338
- Stewart B F, Siscovick D, Lind B K, et al. Clinical factors associated with calcific aortic valve disease: Cardiovascular Health Study. J Am Coll Cardiol. 1997; 29: 630–634
- Otto C M, Lind B K, Kitzman D W, et al. Siscovick DS for the cardiovascular health study. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med 1999; 341: 142–147
- Kumar N, Gilula N B. The gap junction communication channel. Cell 1996; 84: 381–388
- Kwak B R, Veillard N, Pelli G, et al. Reduced connexin43 expression inhibits atherosclerotic lesion formation in low-density lipoprotein receptor-deficient mice. Circulation 2003; 107: 1033–1039
- Stary H C, Bleakley C A, Glagov S, et al. A definition of intitial, fatty streak, and intermediate lesions of atherosclerosis. A report from the committee on vascular lesions of the council on arteriosclerosis, American Heart Association. Circulation 1994; 89: 2462–2478
- Freeman R V, Otto C M. Spectrum of calcific aortic valve disease. Pathogenesis, disease progression, and treatment strategies. Circulation 2005; 111: 3316–3326
- Yumoto K, Ishijima M, Rittling S R, et al. Osteopontin deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice. Proc Natl Acad Sci USA 2002; 99: 4556–4561
- O'Brien E R, Garvin M R, Stewart D K, et al. Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques. Arterioscler Thromb Vasc Biol 1994; 14: 1648–1656
- Kwon H M, Hong B K, Kang T S, et al. Expression of osteopontin in calcified coronary atherosclerotic plaques. J Korean Med Sci. 2000; 15: 485–493
- Parrish A R, Ramos K S. Osteopontin mRNA expression in a chemically-induced model of atherogenesis. Ann NY Acad Sci 1995; 760: 354–356
- Blackburn J P, Peters N S, Yeh H I, et al. Upregulation of connexin43 gap junctions during early stages of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1995; 15: 1219–1228
- Kwak B R, Mulhaupt F, Veillard N, et al. Altered pattern of vascular connexin expression in atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2002; 22: 225–230
- Rennick R E, Connat J L, Burnstock G, et al. Expression of connexin43 gap junctions between cultured vascular smooth muscle cells is dependent upon phenotype. Cell Tissue Res 1993; 271: 323–332
- Kwak B R, Silacci P, Stergiopulos N, et al. Shear stress and cyclic circumferential stretch, but not pressure, alter connexin43 expression in endothelial cells. Cell Commun Adhes 2005; 12: 261–270
- Inai T, Mancuso M R, McDonald D M, et al. Shear stress-induced upregulation of connexin43 expression in endothelial cells on upstream surfaces of rat cardiac valves. Histochem Cell Biol 2004; 122: 477–483
- Rosenhek R, Rader F, Loho N, et al. Statins but not angiotensin-converting enzyme Inhibitors delay progression of aortic stenosis. Circulation 2004; 110: 1291–1295
- Cowell S J, Newby D E, Prescott R J, et al. For the Scottish aortic stenosis and lipid lowering trial, Impact on regression (SALTIRE) investigators. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005; 352: 2389–2397
- Kwak B R, Jongsma H J. Selective inhibition of gap junction channel activity by synthetic peptides. J Physiol 1999; 516: 679–685